Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Catch up with the monthly messages from the Director of the NIHR HTA Programme

OCTRU

Professor Hywel Williams the Director of the NIHR HTA Programme writes a monthly Director’s Message. This month’s message includes Hywel’s tips on how to improve your research application by getting a review from outside of your team, and Hywel’s appreciation of NIHR.

Visit the below You Tube link to see this month's message and previous messages.

https://www.youtube.com/watch?v=6tL5EqPoPGI&index=1&list=PLIa1oelW_zJ-ah4F-3P_hL8G_mdIzSD4q 

Find out more about

Our Groups, Centres and Units

Our Research Themes

Our Clinical Trials

Our Programme Grants

Similar stories

SCIENCE opens in New Zealand

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

PRoCuRe opens to recruitment

The Partial Rotator Cuff Tear Repair Trial (PRoCuRe) is open to recruitment at Oxford University Hospitals NHS Foundation Trust after achieving OCTRU Green Light approval!

FRUITI Trial is given OCTRU Green Light approval

IMP-MEL Trial given Green Light to open

OCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.